Download Product catalogue - TNI medical AG

TNI ® Effectiveness
Mannino et al. (2007), Global burden of COPD: risk factors, prevalence, and future
trends. The Lancet 370:765-773.
14
Therapy
General information about COPD and respiratory insufficiency
Diagnostics
COPD is a disorder of hitherto massively underestimated importance. According to a study published in the
prominent medical professional journal The Lancet, today 10.1% of the entire world population suffers from
this disorder 1 . According to expert estimations, the annual total cost of pulmonary diseases amounts to about a
hundred billion euros alone in Europe. Approximately half of this sum is caused by cases of COPD. In Germany,
the annual costs of COPD is estimated to be
between 5.5 and 8.5 billion euros 2 , and according
to the AOK local health care fund, COPDrelated
disorders already account for 25 million
work disability days a year in Germany 3 . By the
year 2020, COPD is expected to become the
third most frequent cause of death worldwide;
in 2000, 2.7 million people died due to consequences
of the disease 4 .
COPD cannot be cured. Therefore the longterm
breathing therapy used at home in the
course of the disease plays a major role. Apart
from the conventional support with oxygen and
mask respiration, TNI is now introducing a high-
flow breathing therapy with oxygen-air mixture.
This method unites the advantages of an
oxygen therapy with that of oxygen support via mask. The patient is treated in his or her own familiar domestic
environment. With the easily used TNI ® applicator, similar to the nasal applicator, the patient is considerably
more comfortable than when using a comparably effective breathing therapy with mask. In addition, there is a
cost advantage for the health insurance funds.
TNI ® Effectiveness
Current results show that TNI ® 20 oxy significantly improves
blood gas values, and in contrast to simple
oxygen therapy, at low flow rates, and effects not only a rise in
the oxygen saturation, but also a decrease of the CO 2 partial
pressure. This demonstrably supports respiration and reduces the
work of breathing so that the patient perceptibly recovers.
1 Buist AS et al (2007), “International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study” The Lancet
370(9589):741-750
2 Vogelmeier, C et al (2007), “Leitlinie der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin zur
Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD)“ Pneumologie 61: e1-e40
3 Konietzko, N, Fabel H (2000), „Weißbuch Lunge 2000“. Thieme Verlag
4 Maio, S et al (2006), “The global burden of chronic respiratory diseases“ Breathe 3(1): 21-29